Apollo Gleneagles Hospital
Kolkata, West Bengal | India
Main Specialties: Endocrinology Diabetes & Metabolism
Additional Specialties: Diabetology
Dr. Sanjay Chatterjee was born in Calcutta, India in 1952. He passed MBBS (medical graduation) from Nilratan Sircar Medical College under University of Calcutta in 1977. After completion of Internship and one-year House Physician in Internal Medicine, he passed Diploma in Basic Medical Science from University of Calcutta in 1981. He passed M.D. (Doctor of Medicine), University of Calcutta in 1983. His MD thesis on study of serum lipoprotein profile in patients with coronary heart disease was a pioneering work on lipids. He worked in the Diabetes Clinic of RK Mission Seva Pratishthan hospital, Calcutta for more than five years and did research on diabetes. Subsequently, he completed a one-year certificate program on Diabetes Care from University of Newcastle, Australia. He is at present a Senior Consultant in Nutrition and Diabetes at Apollo Gleneagles Hospital, Kolkata (Calcutta), India since 2003. His areas of interest are Diabetes & Metabolic Syndrome and he has several publications in many international journals in these fields. He is a joint editor of three handbooks on diabetes and is an author and moderator of Diapedia, the internet text-book on diabetes, funded by European Association for Study of Diabetes. Dr. Chatterjee is Reviewer and Editorial Board Member for many international journals. He has been Principal Investigator of several international clinical trials.
Dr. Sanjay Chatterjee is a founder member of Integrated Diabetes & Endocrine Academy or, IDEA – an academic organisation for fostering knowledge in the fields of diabetes and endocrinology. The annual conference of IDEA, called IDEACON, is among the most sought-after conferences in its field in India. IDEACON has furthered the prestige of West Bengal in the fields of diabetes and endocrinology.
In August 2017, Dr. Sanjay Chatterjee has been appointed Sheriff of Calcutta by His Excellency Governor of West Bengal.
Primary Affiliation: Apollo Gleneagles Hospital - Kolkata, West Bengal , India
PubMed Central Citations
6PubMed Central Citations
. Diabetes Obes Int J. 2018, May 3(3): 000181
Diabetes and Obesity International Journal ISSN: 2574-7770
Background: Earlier we had reported results of our study of treatment with Saroglitazar, in a dose of 4 mg daily, for 14 weeks in 34 patients with diabetic dyslipidemia., and showed significant improvement in both glycemic and lipid parameters. We conducted this 58 weeks follow-up study in 158 patients to determine whether the improvement in glycemic and lipid parameters persisted in long-term follow-up and whether long-term therapy had any effect on the blood pressure, weight, renal and liver functions. Methods: We have studied follow-up data of 158 patients collected from the authors’ clinic databases and analyzed the effect of saroglitazar on metabolic parameters. Data of patients having both baseline and follow-up data were included in the analysis. The mean duration of follow-up was 58 weeks. Saroglitazar was prescribed at a dose of 4 mg daily, in accordance with approved indication and prescribing information, to patients of T2DM and having hypertriglyceridemia (serum TG level ≥150 mg/dl). Patients received treatment as per routine standard of care without any experimentation on any patient. The patients’ physical parameters (weight, blood pressure etc.), serum lipid profile and glycemic parameters (fasting plasma glucose, post-meal plasma glucose,HbA1C) were determined at baseline and at last follow-up visit. Results: After a mean study duration period of 58 weeks of 158 patients with diabetic dyslipidemia, there was significant reduction in triglycerides from 319.88 ± 178.75 mg/dl (mean ± SD) to 174.03 ± 113.62 mg/dl (reduction of 145.84 ± 186.59 mg/dl; p<0.001). Glycosylated hemoglobin (HbA1c) was reduced from 7.91 ± 1.53% (mean ± SD) to7.25 ± 1.38% (reduction of 0.65 ± 1.37%; p<0.001). Other lipid and glycemic parameters such as total cholesterol, low-density lipoprotein, non-high-density lipoprotein, triglyceride/HDLc ratio, fasting and postprandial plasma glucose were also significantly reduced. There were no major adverse events observed or, reported during the entire study period. Conclusion: Our long-term follow-up study showed that dual PPAR α+γ agonist, saroglitazar, could be an effective and safe therapeutic option in adult patients with diabetic dyslipidemia with a persistent and significant improvement in glycemic and lipid parameters and may confer an additional beneficial effect on blood pressure and liver function as well.
Interv Cardiol Clin. 2018 Jan;7(1):71-80. doi: 10.1016/j.iccl.2017.08.001. Review. PMID: 29157526
Interventional Cardiology Clinics
J Assoc Phys India 2017 July; (65): 51-62
Journal of the Association of Physicians of India
Chatterjee S, Ghosal S, Chatterjee S. Glucagon-like peptide-1 receptor agonists favorably address al
World Journal of Diabetes
Cardiovascular death is the leading cause of mortality for patients with type 2 diabetes mellitus. The etiology of cardiovascular disease in diabetes may be divided into hyperglycemia per se and factors operating through components of metabolic syndrome (MetS). Hyperglycemia causes direct injury to vascular endothelium and possibly on cardiac myocytes. MetS is a cluster of risk factors like obesity, hyperglycemia, hypertension and dyslipidemia. The incidence of this syndrome is rising globally. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a group of drugs, which address all components of this syndrome favorably. Experimental evidence suggests that they have favorable actions on myocardium as well. Several compounds belonging to GLP-1RA class are in market now and a large number awaiting their entry. Although, originally this class of drugs emerged as a treatment for type 2 diabetes mellitus, more recent data generated revealed beneficial effects on multiple metabolic parameters. We have studied literature published between 2000 and 2016 to look into effects of GLP-1RA on components of MetS. Results from recently concluded clinical trials suggest that some of the molecules in this class may have favorable effects on cardiovascular outcome.
Ann Intern Med 2016 Feb;164(4):JC15
Am J Ther 2015 May-Jun;22(3):195-8
1Consultant Physician, Diabetes Clinical Nutrition, Apollo Gleneagles Hospital, Kolkata, India; and 2Fellow, Preventive Cardiology, Brown University & VA Medical Center, Providence, RI.
Chatterjee S, Ghosal S. Strategies to Increase HDL-cholesterol. J Clin Diabetes Metab. (2014). Nov.
Journal of Clinical Diabetes & Metabolism
Coronary heart disease (CHD) is a major cause of morbidity and mortality all over the world. Abnormalities of serum lipids were implicated as an important cause of CHD for a long time.
Majumder A, Chatterjee S (2014) Diabetic Dyslipidemia - Role of
‘Diabetic dyslipidemia’ (combination of raised triglyceride levels, raised small-dense Low-density lipoprotein particles and low high-density lipoprotein cholesterol levels) is the most prominent risk factor of atherosclerosis and cardiovascular disease. Despite statin therapy and LDL-lowering, a high residual risk of cardiovascular events persists. High triglyceride levels and low high-density lipoprotein cholesterol levels singly and collectively increase the risk of cardiovascular events in type 2 diabetes mellitus and guidelines recommend modifying these secondary therapeutic targets to provide additional vascular protection.Addition of a fibrate or niacinareoptions for combination with a statin to reduce atherogenic dyslipidemia and are clearly effective at raising high-density lipoprotein cholesterol levels and lowering triglycerides.Addition of high dose omega-3 fatty acids (2-3 gm/day) with a statin are also effective in lowering triglyceride, but their effects on cardiovascular events remain uncertain and are complicated with safety issues. Saroglitazar is a novel dual Peroxisome Proliferator-Activated Receptors-α/γ agonist and the first glitazar approved in the world for the treatment of diabetic dyslipidemia by Drug Controller General of India in June 2013. Saroglitazar (2 mg and 4 mg) therapy has shown significant (45%) reduction in triglycerides, significant reduction of other atherogenic lipids (Low-density lipoprotein, very-low density lipoprotein, total cholesterol and apolipoprotein-B) and significant improvement of glycemic status, with relatively free from side effects. It has emerged with a hope to further reduce the incidence of cardiovascular disease among statin treated diabetic subjects. However, the trial populations were small and toxicity data may emerge with increasing use of this drug. Moreover, in absence of outcome studies and large multi-center longitudinal follow up data, the clinical cardiovascular efficacy is uncertain till date
J Indian Med Assoc 2013 Nov;111(11):729-32, 734
Ann Intern Med 2013 Apr;158(8):JC8
Indian Medical Journal. 1984 April; 78(4):53 - 55.
Indian Medical Journal